LLY

1,095.21

-2.64%↓

JNJ

226.73

-2.05%↓

ABBV

216.57

-1.01%↓

UNH

379.19

-1.44%↓

MRK

118.67

-1.27%↓

LLY

1,095.21

-2.64%↓

JNJ

226.73

-2.05%↓

ABBV

216.57

-1.01%↓

UNH

379.19

-1.44%↓

MRK

118.67

-1.27%↓

LLY

1,095.21

-2.64%↓

JNJ

226.73

-2.05%↓

ABBV

216.57

-1.01%↓

UNH

379.19

-1.44%↓

MRK

118.67

-1.27%↓

LLY

1,095.21

-2.64%↓

JNJ

226.73

-2.05%↓

ABBV

216.57

-1.01%↓

UNH

379.19

-1.44%↓

MRK

118.67

-1.27%↓

LLY

1,095.21

-2.64%↓

JNJ

226.73

-2.05%↓

ABBV

216.57

-1.01%↓

UNH

379.19

-1.44%↓

MRK

118.67

-1.27%↓

Home・Elenco Azioni・Editas Medicine Inc

Editas Medicine Inc

Aperta

SettoreSettore sanitario

3.37 -2.03

Acquista Vendi

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

3.24

Massimo

3.52

Metriche Chiave
By Trading Economics
Entrata	-19M -25M
Vendite	-22M 2.8M
EPS	-0.26
Margine di Profitto	-882.444
Dipendenti	87
EBITDA	-19M -25M

Raccomandazioni
By TipRanks
Raccomandazioni	Acquista
Previsioni per 12 mesi	+78.43% upside

Dividendi
By Dow Jones
Utili prossimi	10 ago 2026

Statistiche di mercato
By TradingEconomics
Capitalizzazione di Mercato	-40M 254M
Apertura precedente	5.4
Chiusura precedente	3.37

Notizie sul Sentiment di mercato

By Acuity

21%

79%

38 / 344 Classifica in Healthcare

Editas Medicine Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

28 mag 2026, 22:47 UTC

Utili

Costco 3Q Sales Rise as Value Offerings Draw Pressured Consumers -- Update

28 mag 2026, 20:45 UTC

Utili

Costco 3Q Profit Rises as Value Offerings Draw Pressured Consumers

28 mag 2026, 23:43 UTC

Discorsi di Mercato

Nikkei May Rise on Hopes for U.S.-Iran Peace Deal -- Market Talk

28 mag 2026, 23:39 UTC

Discorsi di Mercato

Gold Edges Lower as Traders Assess Potential U.S.-Iran Deal -- Market Talk

28 mag 2026, 23:31 UTC

Discorsi di Mercato

KMD Could Realize Value From Selling Either Oboz or Rip Curl -- Market Talk

28 mag 2026, 23:17 UTC

Discorsi di Mercato

Mainfreight Steering Its Way Out of Tough Period -- Market Talk

28 mag 2026, 23:02 UTC

Discorsi di Mercato

Costco Has Started Submitting Tariff Refund Claims -- Market Talk

28 mag 2026, 22:41 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

28 mag 2026, 22:41 UTC

Discorsi di Mercato

MongoDB Still Getting More Growth From Established Customers Than AI -- Market Talk

28 mag 2026, 22:37 UTC

Discorsi di Mercato

Acquisizioni, Fusioni, Takeovers

M&A-Related Insurance Payments In North America Rise -- Market Talk

28 mag 2026, 22:04 UTC

Acquisizioni, Fusioni, Takeovers

CN: Surface Transportation Board Was Right to Freeze the UP-NS Merger and Demand More Info

28 mag 2026, 22:04 UTC

Acquisizioni, Fusioni, Takeovers

CN: This Confirms What CN and Many Stakeholders Have Said All Along, UP and NS Still Have Not Submitted a Credible Case to Support Their Proposed Merger >CNI

28 mag 2026, 21:12 UTC

Utili

Acquisizioni, Fusioni, Takeovers

Synopsys Was the Worst S&P 500 Stock Thursday Despite Earnings Beat With AI and Merger in Focus -- Barrons.com

28 mag 2026, 21:00 UTC

Utili

Dell Stock Soars on Blowout Earnings. The Outlook Bests Analysts by $20 Billion. -- Barrons.com

28 mag 2026, 20:57 UTC

Utili

Dell Stock Soars on Blowout Earnings -- Barrons.com

28 mag 2026, 20:55 UTC

Utili

Costco Wholesale Sees a Mixed Quarter, Misses Earnings Estimates -- Barrons.com

28 mag 2026, 20:50 UTC

Discorsi di Mercato

Tech, Media & Telecom Roundup: Market Talk

28 mag 2026, 20:50 UTC

Discorsi di Mercato

Financial Services Roundup: Market Talk

28 mag 2026, 20:50 UTC

Discorsi di Mercato

Basic Materials Roundup: Market Talk

28 mag 2026, 20:48 UTC

Azioni calde

Stocks to Watch Recap: Snowflake, Union Pacific, Hormel Foods -- WSJ

28 mag 2026, 20:34 UTC

Utili

One of the S&P 500's Highest Dividends Looks Even Better Now -- Barrons.com

28 mag 2026, 20:31 UTC

Utili

Li and XPeng Both Miss Earnings Estimates. One Chinese EV Maker's Stock Is Rising. -- Barrons.com

28 mag 2026, 20:28 UTC

Utili

Best Buy's 5% Dividend Yield Looks Even Better After Earnings -- Barrons.com

28 mag 2026, 20:26 UTC

Utili

Dell Stock Soars on Blowout Earnings -- Barrons.com

28 mag 2026, 20:20 UTC

Utili

Costco 3Q Membership Fees $1.37B

28 mag 2026, 20:20 UTC

Utili

Costco 3Q Net Sales $69.15B

28 mag 2026, 20:19 UTC

Utili

Costco 3Q Adj Same-Store Sales, Which Excludes Impacts From Gas Prices and Foreign Exchange, Rose 6.6% >COST

28 mag 2026, 20:19 UTC

Utili

Costco 3Q Adjusted Digitally-Enabled Sales Rose 20.8% >COST

28 mag 2026, 20:17 UTC

Utili

Costco 3Q Digitally-Enabled Sales Rose 21.5% >COST

28 mag 2026, 20:17 UTC

Utili

Costco 3Q Same-Store Sales Up 9.8% >COST

Confronto tra pari

Modifica del prezzo

Editas Medicine Inc Previsione

Obiettivo di Prezzo

By TipRanks

78.43% in crescita

Previsioni per 12 mesi

Media 6.37 USD 78.43%

Alto 15 USD

Basso 4 USD

Basato su 11 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Editas Medicine Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Acquista

11 ratings

Acquista

Mantieni

Vendi

Basato sugli analisti di 11 che hanno fornito valutazioni azionarie a Editas Medicine Inc - Dist negli ultimi 3 mesi.

Sentiment

By Acuity

38 / 344 Classifica in Settore sanitario

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

Chi Siamo Editas Medicine Inc

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing alpha-beta T cells for solid and liquid tumors; and gamma delta T cell therapies to treat cancer. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; collaboration and nonexclusive license agreement with Genevant Sciences to develop Novel mRNA-LNP gene editing therapeuticsand strategic alliance and option agreement with Allergan Pharmaceuticals International Limited, as well as collaboration with Bristol Myers Squibb for research and development of alpha-beta T cell medicines for the treatment of cancer and autoimmune diseases. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.